Tolazamide

Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor) . Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA[1][2][3].

Product Specifications

CAS Number

[1156-19-0]

Product Name Alternative

U-17835

UNSPSC

12352005

Hazard Statement

H302

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Tolazamide.html

Purity

99.94

Solubility

DMSO : ≥ 39 mg/mL

Smiles

O=S(C1=CC=C(C)C=C1)(NC(NN2CCCCCC2)=O)=O

Molecular Formula

C14H21N3O3S

Molecular Weight

311.40

Precautions

H302

References & Citations

[1]Mustafa Karakaya, et al., (2015) Theoretical and experimental investigations on vibrational and structural properties of tolazamide, Journal of Molecular Structure, Volume 1095, Pages 87-95, ISSN 0022-2860. |[2]Gopalakrishnan, M., et al., (2000) . Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K (+) channel Kir6.2 combination expressed in HEK-293 cells. British journal of pharmacology, 129 (7), 1323–1332.|[3]Kabadi U. M. (1985) . Adjuvant therapy with tolazamide and insulin improves metabolic control in type I diabetes mellitus. Diabetes care, 8 (5), 440–446.|[4]McCormick, K., et al., (1986) . Effect of tolazamide on basal ketogenesis, glycogenesis, and gluconeogenesis in liver obtained from normal and diabetic rats. Endocrinology, 119 (3), 1268–1273.